1. Home
  2. CLGN vs LSTA Comparison

CLGN vs LSTA Comparison

Compare CLGN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLGN
  • LSTA
  • Stock Information
  • Founded
  • CLGN 2004
  • LSTA 1980
  • Country
  • CLGN Israel
  • LSTA United States
  • Employees
  • CLGN N/A
  • LSTA N/A
  • Industry
  • CLGN Industrial Specialties
  • LSTA Misc Health and Biotechnology Services
  • Sector
  • CLGN Health Care
  • LSTA Health Care
  • Exchange
  • CLGN Nasdaq
  • LSTA Nasdaq
  • Market Cap
  • CLGN 19.1M
  • LSTA 22.5M
  • IPO Year
  • CLGN N/A
  • LSTA N/A
  • Fundamental
  • Price
  • CLGN $2.31
  • LSTA $2.69
  • Analyst Decision
  • CLGN Strong Buy
  • LSTA Strong Buy
  • Analyst Count
  • CLGN 2
  • LSTA 2
  • Target Price
  • CLGN $11.50
  • LSTA $23.50
  • AVG Volume (30 Days)
  • CLGN 69.8K
  • LSTA 56.3K
  • Earning Date
  • CLGN 08-19-2025
  • LSTA 08-11-2025
  • Dividend Yield
  • CLGN N/A
  • LSTA N/A
  • EPS Growth
  • CLGN N/A
  • LSTA N/A
  • EPS
  • CLGN N/A
  • LSTA N/A
  • Revenue
  • CLGN $2,472,000.00
  • LSTA $1,000,000.00
  • Revenue This Year
  • CLGN $1,999.42
  • LSTA N/A
  • Revenue Next Year
  • CLGN $69.81
  • LSTA N/A
  • P/E Ratio
  • CLGN N/A
  • LSTA N/A
  • Revenue Growth
  • CLGN N/A
  • LSTA N/A
  • 52 Week Low
  • CLGN $1.31
  • LSTA $1.87
  • 52 Week High
  • CLGN $5.45
  • LSTA $4.20
  • Technical
  • Relative Strength Index (RSI)
  • CLGN 65.19
  • LSTA 52.66
  • Support Level
  • CLGN $2.16
  • LSTA $2.45
  • Resistance Level
  • CLGN $2.28
  • LSTA $2.74
  • Average True Range (ATR)
  • CLGN 0.18
  • LSTA 0.27
  • MACD
  • CLGN 0.11
  • LSTA -0.00
  • Stochastic Oscillator
  • CLGN 86.24
  • LSTA 51.81

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: